UNSPSC 51113102: Mitobronitol

This classification denotes a biomaterial with the molecular formula C6H12Br2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5UP30YED7N, chemically known as 1,2,3,4,5,6-hexanehexol but more generally known as mitobronitol, which bears US NIH Compound Identifier 453. European Medicines Agency schedules Mitobronitol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09001MIG.

UNSPSC 51113102 Mitobronitol, a Commodity code, covers pharmaceutical active ingredients and specialty chemicals procured by state health agencies for pharmacy benefit programs and therapeutic initiatives. The recent activity under this code reflects state procurement of prescription pharmaceuticals and related pharmacy services delivered through direct-to-manufacturer contracting models that bypass traditional pharmacy benefit manager and group purchasing organization intermediaries. State and local governments are buying access to direct pharmaceutical supply channels, negotiated pricing arrangements, and outcomes-based pharmacy management capabilities that improve cost control and prescription fulfillment efficiency within state employee health plans and Medicaid programs.

The Texas Health and Human Services Commission posted RFI No. HHS0017013 on April 3, 2026, seeking vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI targets vendors with experience in direct contracting for self-insured employers and health plans, negotiated net pricing models without rebates, and value-based or outcomes-based agreement implementation. The solicitation seeks information on vendors' ability to fulfill product volume requirements, pharmacy partner dependencies, and participation in purchasing organizations serving multiple government jurisdictions. No award value, budget range, or formal evaluation criteria are specified in this preliminary market-intelligence phase; the state intends to use vendor responses to develop detailed procurement specifications and implementation timelines for subsequent formal solicitations. Activity under this code appears concentrated in state health agencies managing pharmacy benefits, with limited recent breadth across other issuing-body types.